Dublin, Aug. 29, 2016 -- Research and Markets has announced the addition of the "Transplantation Diagnostics Global Market - Forecast to 2022" report to their offering.
The transplantation diagnostics global market is expected to grow at a high CAGR to reach $2,059.2 million in 2022
Increased incidence of life style diseases like cancer, diabetes, heart diseases etc., associated with unhealthy habits are likely to damage the organs or tissues, requiring the necessity of transplantation procedures, which is simultaneously expected to propel the growth of transplantation diagnostics market.
Along with these the rising disposable incomes in the developing countries, rapid growth in aging and diseased population provides an opportunity for IVD companies to come up with more number of tests. However some issues like high test cost, limited reimbursement facility, and some ethical issues may hinder the growth of transplantation diagnostics market. If these issues are addressed, there will be a huge growth potential for transplantation diagnostics with added opportunities from new avenues like cell-free DNA which is likely to propel the market with very high growth rate.
The transplantation diagnostics global market is segmented by technology, products, applications, end users, and by geography. The technology market is segmented into two main divisions such as molecular methods and non-molecular methods. Non-Molecular methods market held the largest market revenue and the molecular methods are expected to grow by 2022 growing at a high CAGR from 2015 to 2022, due to the greater sensitivity, accuracy, and resolving power compared to serological typing methods. The transplantation diagnostics market by product type is segmented into three major divisions such as instruments, reagents & consumables and software & services.
Among these, consumables accounts for largest share and is growing strongly at a double digit CAGR due to availability of easy-to-use assay kits for HLA typing based on SSP-PCR, SSOPCR, NGS and serological tests. The transplantation diagnostics market by applications is segmented into two major divisions such as diagnostic and research. Among these, diagnostic accounts for the largest share growing strongly at a double digit CAGR.
The transplantation diagnostics market by end-users is segmented into three major divisions such as hospital & transplant centres, diagnostic laboratories and research laboratories, and academic institutions. Among these, hospital and transplant centres accounts for highest share in 2015 are expected to grow by 2022 growing at a high CAGR from 2015 to 2022.
Key Topics Covered:
1 Executive Summary
2 Introduction
3 Market Analysis
4 Transplantation Diagnostics Global Market, By Technology
5 Transplantation Diagnostics Global Market, By Product Type
6 Transplantation Diagnostics Global Market, By Screening Methods
7 Transplantation Diagnostics Global Market, By Application
8 Transplantation Diagnostics Global Market, By End-Users
9 Transplantation Diagnostics Global Market, By Region
10 Company Developments
11 Company Profiles
- Abbott Laboratories, Inc.
- Bio-Rad Laboratories
- Biofortuna Ltd
- Caredx, Inc.
- Illumina, Inc.
- Immucor, Inc.
- Linkage Biosciences, Inc.
- Qiagen N.V.
- Roche Holdings Ag
- Thermo Fisher Scientific, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/39sth2/transplantation
Related Topics: Diagnostics
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



